Thus, the combination of BTK and MALT1 inhibitors apparently additively increases the efficacy over single agent treatment to suppress expression of NF-κB dependent pro-survival proteins in ABC DLBCL cells. The gene discussed is MALT1; the disease is diffuse large B-cell lymphoma.